Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18907366 | 1.00 | DPP4 (0.32) | DPP4 | |
| SCHEMBL18909888 | 1.00 | DPP4 (0.32) | DPP4 | |
| SCHEMBL888942 | 0.81 | DPP4 (0.31) | DPP4 | |
| SCHEMBL888789 | 0.81 | DPP4 (0.31) | DPP4 | |
| SCHEMBL27414962 | 0.79 | DPP4 (0.31) | DPP4 | |
| SCHEMBL22648833 | 0.78 | DPP4 (0.32) | DPP4 | |
| SCHEMBL4157626 | 0.77 | MLYCD (0.31) | DPP4 | |
| SCHEMBL807050 | 0.77 | ALDH1A1 (0.35) | DPP4 | |
| SCHEMBL14984981 | 0.77 | ALDH1A1 (0.35) | DPP4 | |
| SCHEMBL14984976 | 0.77 | ALDH1A1 (0.35) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240058259-A1 | COMPOSITIONS COMPRISING ESSENTIAL OILS | FIRMENICH SA (CH) | 2024-02-22 | — | — | US | claimed |
| CN-112402284-A | Preparation method of liquid cooling agent | 安徽丰乐香料有限责任公司 | 2021-02-26 | — | — | CN | disclosed |
| EP-3380478-B1 | ESTER ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO LLC (US) | 2020-12-23 | — | — | EP | disclosed |
| WO-2020114471-A1 | COOL COMPONENT FORMULATION FOR ENHANCING COOLNESS OF WINE AND PREPARATION METHOD THEREFOR | 昆山亚香香料股份有限公司 | 2020-06-11 | — | — | WO | disclosed |
| US-20170166582-A1 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| US-20170166583-A1 | ESTER ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| US-20170166582-A1 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| US-20170166583-A1 | ESTER ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| EP-2200566-A1 | IMPROVED TOPICAL PAIN RELIEF PRODUCT | McNeil-PPC, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090098173-A1 | TOPICAL PAIN RELIEF PRODUCT | MCNEIL-PPC, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2009049190-A1 | IMPROVED TOPICAL PAIN RELIEF PRODUCT | MCNEIL-PPC, INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| EP-1987196-A2 | FIBROUS STRUCTURES COMPRISING VOLATILE AGENTS | The Procter and Gamble Company (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007100665-A2 | FIBROUS STRUCTURES COMPRISING VOLATILE AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070196405-A1 | Fibrous structures comprising volatile agents | THE PROCTER & GAMBLE COMPANY | 2007-08-23 | — | — | US | disclosed |
| US-20070059417-A1 | Cooling agents as flavor and saltiness enhancers | MOZA ASHOK K | 2007-03-15 | — | — | US | disclosed |
| US-20070048424-A1 | Liquid composition of 2-Isopropyl-N,2,3-trimethylbutyramide and N-Ethyl-p-menthane-3-carboxamide, its preparation method and its applications as a cooling agent and flavor enhancer | MOZA ASHOK K | 2007-03-01 | — | — | US | disclosed |
| US-20070009442-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166583-A1 | ESTER ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | DPP4 558/4885 |
| US-20070196405-A1 | Fibrous structures comprising volatile agents | VIM, PFAS, FABP4 | DPP4 3359/4885 |
| US-20170166582-A1 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, PC | DPP4 829/4885 |
| US-20070009442-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | CA13, MPI, CA14 | DPP4 1528/4885 |
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT1 | DPP4 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.